Ignite Creation Date:
2025-12-24 @ 1:15 PM
Ignite Modification Date:
2025-12-28 @ 5:51 AM
Study NCT ID:
NCT05361395
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-11-25
First Post:
2022-04-29
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Sponsor:
Amgen
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-08-24
Start Date Type:
ACTUAL
Primary Completion Date:
2028-08-28
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-08-28
Completion Date Type:
ESTIMATED
First Submit Date:
2022-04-29
First Submit QC Date:
None
Study First Post Date:
2022-05-04
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-20
Last Update Post Date:
2025-11-25
Last Update Post Date Type:
ESTIMATED